| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/03/2023 | 60.01% | RBC Capital | $180 → $125 | Maintains | Outperform |
| 11/03/2023 | 195.7% | Goldman Sachs | $269 → $231 | Maintains | Buy |
| 11/03/2023 | -11.67% | HSBC | $89 → $69 | Upgrades | Reduce → Hold |
| 11/02/2023 | — | Deutsche Bank | Downgrades | Hold → Sell | |
| 09/13/2023 | 79.21% | Argus Research | $160 → $140 | Maintains | Buy |
| 08/04/2023 | 57.45% | Morgan Stanley | $128 → $123 | Maintains | Equal-Weight |
| 08/04/2023 | 92.01% | B of A Securities | $175 → $150 | Maintains | Neutral |
| 08/04/2023 | 143.22% | RBC Capital | $200 → $190 | Maintains | Outperform |
| 08/04/2023 | 60.01% | TD Cowen | $145 → $125 | Downgrades | Outperform → Market Perform |
| 08/03/2023 | 60.01% | Deutsche Bank | $200 → $125 | Downgrades | Buy → Hold |
| 07/24/2023 | 111.21% | TD Cowen | $175 → $165 | Maintains | Outperform |
| 07/24/2023 | — | William Blair | Initiates Coverage On | → Market Perform | |
| 07/14/2023 | 24.17% | HSBC | → $97 | Initiates Coverage On | → Reduce |
| 07/11/2023 | 63.85% | Morgan Stanley | $153 → $128 | Maintains | Equal-Weight |
| 06/26/2023 | 144.5% | UBS | $221 → $191 | Upgrades | Neutral → Buy |
| 05/05/2023 | 147.06% | Morgan Stanley | $185 → $193 | Maintains | Equal-Weight |
| 04/26/2023 | — | Guggenheim | Initiates Coverage On | → Neutral | |
| 04/12/2023 | 79.21% | JP Morgan | $145 → $140 | Maintains | Neutral |
| 04/10/2023 | 85.61% | JP Morgan | $127 → $145 | Maintains | Neutral |
| 03/13/2023 | 130.41% | TD Cowen | $150 → $180 | Upgrades | Market Perform → Outperform |
| 03/02/2023 | 156.02% | RBC Capital | → $200 | Initiates Coverage On | → Outperform |
| 02/28/2023 | 156.02% | Deutsche Bank | $225 → $200 | Maintains | Buy |
| 02/24/2023 | 19.05% | SVB Leerink | $111 → $93 | Downgrades | Market Perform → Underperform |
| 02/08/2023 | 76.65% | JP Morgan | $132 → $138 | Maintains | Neutral |
| 01/25/2023 | 92.01% | Cowen & Co. | $130 → $150 | Maintains | Market Perform |
| 01/24/2023 | 162.42% | Morgan Stanley | $209 → $205 | Maintains | Equal-Weight |
| 01/18/2023 | 42.09% | SVB Leerink | $102 → $111 | Maintains | Market Perform |
| 01/18/2023 | 166.26% | Chardan Capital | $191 → $208 | Maintains | Neutral |
| 12/20/2022 | 177.78% | Piper Sandler | $214 → $217 | Maintains | Overweight |
| 12/19/2022 | 252.02% | Jefferies | $170 → $275 | Upgrades | Hold → Buy |
| 12/16/2022 | 167.54% | Morgan Stanley | $170 → $209 | Maintains | Equal-Weight |
| 12/14/2022 | 144.5% | Chardan Capital | $186 → $191 | Downgrades | Buy → Neutral |
| 12/13/2022 | 30.57% | SVB Leerink | $101 → $102 | Maintains | Market Perform |
| 11/07/2022 | 138.1% | Chardan Capital | $188 → $186 | Maintains | Buy |
| 11/04/2022 | 117.61% | Morgan Stanley | $175 → $170 | Maintains | Equal-Weight |
| 10/24/2022 | 56.17% | JP Morgan | $165 → $122 | Maintains | Neutral |
| 10/21/2022 | 29.29% | SVB Leerink | $74 → $101 | Upgrades | Underperform → Market Perform |
| 10/18/2022 | 124.01% | Morgan Stanley | $197 → $175 | Maintains | Equal-Weight |
| 10/13/2022 | 278.9% | Goldman Sachs | $290 → $296 | Maintains | Buy |
| 09/14/2022 | 92.01% | Argus Research | $180 → $150 | Maintains | Buy |
| 09/08/2022 | 111.21% | Deutsche Bank | $155 → $165 | Upgrades | Hold → Buy |
| 08/04/2022 | 152.18% | Morgan Stanley | $199 → $197 | Maintains | Equal-Weight |
| 08/04/2022 | -5.27% | SVB Leerink | $77 → $74 | Maintains | Underperform |
| 08/01/2022 | -1.43% | SVB Leerink | $70 → $77 | Maintains | Underperform |
| 06/07/2022 | -10.39% | SVB Leerink | $80 → $70 | Maintains | Underperform |
| 05/18/2022 | 173.94% | Piper Sandler | $348 → $214 | Maintains | Overweight |
| 05/05/2022 | 154.74% | Morgan Stanley | $217 → $199 | Maintains | Equal-Weight |
| 04/12/2022 | 177.78% | Morgan Stanley | $205 → $217 | Maintains | Equal-Weight |
| 03/25/2022 | 2.41% | SVB Leerink | $81 → $80 | Maintains | Underperform |
| 03/07/2022 | 98.41% | Deutsche Bank | $175 → $155 | Maintains | Hold |
| 02/28/2022 | 162.42% | Morgan Stanley | $213 → $205 | Maintains | Equal-Weight |
| 02/25/2022 | 3.69% | SVB Leerink | $85 → $81 | Maintains | Underperform |
| 02/01/2022 | 172.66% | Morgan Stanley | $315 → $213 | Maintains | Equal-Weight |
| 01/28/2022 | 8.81% | SVB Leerink | $86 → $85 | Maintains | Underperform |
| 01/26/2022 | 124.01% | Deutsche Bank | → $175 | Upgrades | Sell → Hold |
| 01/21/2022 | 182.9% | UBS | → $221 | Initiates Coverage On | → Neutral |
| 01/21/2022 | 130.41% | B of A Securities | $135 → $180 | Upgrades | Underperform → Neutral |
| 01/18/2022 | 303.23% | Morgan Stanley | $313 → $315 | Maintains | Equal-Weight |
| 12/07/2021 | 220.02% | Cowen & Co. | → $250 | Initiates Coverage On | → Market Perform |
| 11/09/2021 | 289.14% | Wolfe Research | → $304 | Initiates Coverage On | → Outperform |
| 11/05/2021 | 10.09% | SVB Leerink | $85 → $86 | Maintains | Underperform |
| 11/05/2021 | 417.15% | Barclays | $463 → $404 | Maintains | Overweight |
| 11/05/2021 | 300.67% | Morgan Stanley | $337 → $313 | Maintains | Equal-Weight |
| 11/05/2021 | 316.03% | Jefferies | $375 → $325 | Maintains | Hold |
| 11/05/2021 | 405.63% | Goldman Sachs | $461 → $395 | Maintains | Buy |
| 10/22/2021 | 220.02% | Deutsche Bank | → $250 | Initiates Coverage On | → Sell |
| 10/15/2021 | — | Piper Sandler | Upgrades | Neutral → Overweight | |
| 09/07/2021 | 331.39% | Morgan Stanley | $190 → $337 | Maintains | Equal-Weight |
| 08/06/2021 | 492.68% | Barclays | $194 → $463 | Maintains | Overweight |
| 08/06/2021 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 08/06/2021 | 469.64% | Piper Sandler | $246 → $445 | Downgrades | Overweight → Neutral |
| 07/15/2021 | 220.02% | Jefferies | $170 → $250 | Maintains | Hold |
| 06/24/2021 | 194.42% | Argus Research | $200 → $230 | Maintains | Buy |
| 05/07/2021 | 140.66% | Chardan Capital | $182 → $188 | Maintains | Buy |
| 05/07/2021 | 143.22% | Morgan Stanley | $201 → $190 | Maintains | Equal-Weight |
| 05/07/2021 | 191.86% | Goldman Sachs | $206 → $228 | Maintains | Buy |
| 04/15/2021 | 199.54% | Piper Sandler | $208 → $234 | Reiterates | → Overweight |
| 03/15/2021 | 166.26% | Piper Sandler | → $208 | Reiterates | → Overweight |
| 03/01/2021 | 132.97% | Chardan Capital | $107 → $182 | Maintains | Buy |
| 02/26/2021 | 162.42% | Brookline Capital | $180 → $205 | Maintains | Buy |
| 02/26/2021 | 157.3% | Morgan Stanley | $215 → $201 | Maintains | Equal-Weight |
| 02/18/2021 | 175.22% | Morgan Stanley | $150 → $215 | Maintains | Equal-Weight |
| 02/17/2021 | 166.26% | Piper Sandler | $170 → $208 | Maintains | Overweight |
| 02/01/2021 | 163.7% | Oppenheimer | $178 → $206 | Maintains | Outperform |
| 02/01/2021 | 85.61% | Wells Fargo | $129 → $145 | Maintains | Equal-Weight |
| 02/01/2021 | — | B of A Securities | Downgrades | Neutral → Underperform | |
| 02/01/2021 | 2.41% | SVB Leerink | $69 → $80 | Maintains | Underperform |
| 01/22/2021 | 79.21% | B of A Securities | $130 → $140 | Maintains | Neutral |
| 12/16/2020 | 92.01% | Morgan Stanley | $100 → $150 | Downgrades | Overweight → Equal-Weight |
| 12/16/2020 | 92.01% | Jefferies | $90 → $150 | Downgrades | Buy → Hold |
| 12/09/2020 | — | Needham | Downgrades | Buy → Hold | |
| 12/01/2020 | 156.02% | Argus Research | $88 → $200 | Maintains | Buy |
| 11/24/2020 | -23.2% | SVB Leerink | $59 → $60 | Maintains | Underperform |
| 11/23/2020 | 17.77% | Wells Fargo | → $92 | Initiates Coverage On | → Equal-Weight |
| 11/17/2020 | 36.97% | Chardan Capital | $93 → $107 | Maintains | Buy |
| 11/17/2020 | — | Redburn Partners | Initiates Coverage On | → Sell | |
| 11/17/2020 | 39.53% | BMO Capital | → $109 | Downgrades | Outperform → Market Perform |
| 11/11/2020 | 28.01% | Morgan Stanley | $90 → $100 | Maintains | Overweight |
| 10/09/2020 | 19.05% | Chardan Capital | $95 → $93 | Maintains | Buy |
| 09/08/2020 | -47.52% | SVB Leerink | $58 → $41 | Downgrades | Market Perform → Underperform |
| 08/12/2020 | -25.76% | SVB Leerink | $60 → $58 | Maintains | Market Perform |
| 08/06/2020 | -23.2% | SVB Leerink | $65 → $60 | Maintains | Market Perform |
| 07/23/2020 | -16.79% | SVB Leerink | → $65 | Initiates Coverage On | → Market Perform |
| 07/20/2020 | 13.93% | JP Morgan | $60 → $89 | Downgrades | Overweight → Neutral |
| 07/15/2020 | 21.61% | Chardan Capital | $84 → $95 | Maintains | Buy |
| 07/13/2020 | 21.61% | Brookline Capital | → $95 | Initiates Coverage On | → Buy |
| 07/13/2020 | 15.21% | Jefferies | → $90 | Initiates Coverage On | → Buy |
| 06/08/2020 | -12.95% | Barclays | → $68 | Initiates Coverage On | → Overweight |
| 05/20/2020 | 15.21% | Morgan Stanley | $37 → $90 | Maintains | Overweight |
| 05/19/2020 | 43.37% | BMO Capital | $83 → $112 | Maintains | Outperform |
| 05/19/2020 | 21.61% | B of A Securities | $70 → $95 | Maintains | Neutral |
| 05/18/2020 | 34.41% | Goldman Sachs | $63 → $105 | Maintains | Buy |
| 05/07/2020 | -25.76% | Needham | $35 → $58 | Maintains | Buy |
| 04/30/2020 | 6.25% | BMO Capital | → $83 | Initiates Coverage On | → Outperform |
| 04/28/2020 | -33.44% | Chardan Capital | $40 → $52 | Maintains | Buy |
| 04/15/2020 | -52.64% | Morgan Stanley | $30 → $37 | Maintains | Overweight |
| 04/15/2020 | -44.96% | Oppenheimer | $31 → $43 | Maintains | Outperform |
| 03/05/2020 | — | B of A Securities | Downgrades | Buy → Neutral | |
| 02/26/2020 | -55.2% | Needham | $28 → $35 | Maintains | Buy |
| 12/03/2019 | -62.88% | B of A Securities | → $29 | Reinstates | → Buy |
| 04/05/2019 | -48.8% | Chardan Capital | → $40 | Initiates Coverage On | → Buy |
| 01/02/2019 | -62.88% | Morgan Stanley | → $29 | Initiates Coverage On | → Overweight |
| 01/02/2019 | -74.4% | Barclays | → $20 | Initiates Coverage On | → Overweight |
| 01/02/2019 | -74.4% | B of A Securities | → $20 | Initiates Coverage On | → Buy |
| 01/02/2019 | -68% | Goldman Sachs | → $25 | Initiates Coverage On | → Buy |
| 01/02/2019 | -64.16% | Needham | → $28 | Initiates Coverage On | → Buy |
| 01/02/2019 | -65.44% | Oppenheimer | → $27 | Initiates Coverage On | → Outperform |
| 01/02/2019 | -71.84% | JP Morgan | → $22 | Initiates Coverage On | → Overweight |
| 01/02/2019 | -69.28% | Piper Sandler | → $24 | Initiates Coverage On | → Overweight |
What is the target price for Moderna (MRNA)?
The latest price target for Moderna (NASDAQ: MRNA) was reported by RBC Capital on November 3, 2023. The analyst firm set a price target for $125.00 expecting MRNA to rise to within 12 months (a possible 60.01% upside). 35 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Moderna (MRNA)?
The latest analyst rating for Moderna (NASDAQ: MRNA) was provided by RBC Capital, and Moderna maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Moderna (MRNA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Moderna, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Moderna was filed on November 3, 2023 so you should expect the next rating to be made available sometime around November 3, 2024.
Is the Analyst Rating Moderna (MRNA) correct?
While ratings are subjective and will change, the latest Moderna (MRNA) rating was a maintained with a price target of $180.00 to $125.00. The current price Moderna (MRNA) is trading at is $78.12, which is out of the analyst's predicted range.